Analyzing VYNE Therapeutics (NASDAQ:VYNE) and Skye Bioscience (NASDAQ:SKYE)

Skye Bioscience (NASDAQ:SKYE) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Skye Bioscience and VYNE Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	0	0	6	0	3.00
VYNE Therapeutics	0	0	2	0	3.00

Skye Bioscience presently has a consensus price target of $18.67, indicating a potential upside of 508.03%. VYNE Therapeutics has a consensus price target of $6.88, indicating a potential upside of 60.63%. Given Skye Bioscience’s higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than VYNE Therapeutics.

Profitability

This table compares Skye Bioscience and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-45.78%	-37.44%
VYNE Therapeutics	-6,896.55%	-43.73%	-38.55%

Valuation and Earnings

This table compares Skye Bioscience and VYNE Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$37.65 million	N/A	N/A
VYNE Therapeutics	$493,000.00	128.06	-$28.45 million	($0.86)	-4.98

VYNE Therapeutics has higher revenue and earnings than Skye Bioscience.

Institutional and Insider Ownership

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.0% of Skye Bioscience shares are owned by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Skye Bioscience has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

About Skye Bioscience

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.